Follow the 엔젠바이오 stock price and the full insider trade history of the company, a listed issuer based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 엔젠바이오 has logged 86 reports. Market capitalisation: €21.5bn. The latest transaction was disclosed on 10 July 2026 (Other). Among the most active insiders: 최대출. All data is openly available.
81
Insider Decl.
n/a
Thresholds
n/a
27 ops.
Buy Volume
n/a
21 ops.
Sell Volume
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,392 of 28,958 companies
9.7
score / 100
Value
6
Quality
13
FCF yld-47%
Earn yld-30%
EV/EBITDA·
ROE-29%
Gross mgn18%
Net mgn-26%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Enzenbio is a company in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for the diagnosis and treatment of diseases.